LPL and breast carcinoma: A clinical investigation involving 24 breast cancer patients administered CLA orally at 7.5 g/day for 20 days revealed inhibition in the expression of fatty acid synthase (FASN) and lipoprotein lipase (LPL), indicating breast tumor growth suppression.